,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Feb 2011', 'fs': 'Feb 2011', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000002pPkS2AU'}, 'Id': 'a0POZ000002pPkS2AU', 'Event_Date__c': '2011-02-22', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Feb 2011', 'Status_History__c': 'a132P000000Apn9QAC'}, 'change': None}]",Feb 2011,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2011', 'fs': 'Mar 2011', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000002pPkT2AU'}, 'Id': 'a0POZ000002pPkT2AU', 'Event_Date__c': '2011-03-09', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Mar 2011', 'Status_History__c': 'a132P000000ApnZQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Cost Neutral', 'fs': 'Cost Neutral', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2011-05.pdf "" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2011-05.pdf "" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'May 2011', 'fs': 'May 2011', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 5 May 2011.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 5 May 2011.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000002pPkV2AU'}, 'Id': 'a0POZ000002pPkV2AU', 'Event_Date__c': '2011-05-05', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 5 May 2011.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2011-05.pdf "" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Cost Neutral', 'Formatted_Date__c': 'May 2011', 'Status_History__c': 'a132P000000AppFQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2011', 'fs': 'Oct 2011', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000002pPkW2AU'}, 'Id': 'a0POZ000002pPkW2AU', 'Event_Date__c': '2011-10-01', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Oct 2011', 'Status_History__c': 'a132P000000AptqQAC'}, 'change': None}, {'Summary': {'s': 'Clarification of May 2011 PTAC minute for ustekinumab (Stelara) for severe chronic plaque psoriasis', 'fs': 'Clarification of May 2011 PTAC minute for ustekinumab (Stelara) for severe chronic plaque psoriasis', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Cost Neutral', 'fs': 'Cost Neutral', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2011-11.pdf "" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2011-11.pdf "" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'Nov 2011', 'fs': 'Nov 2011', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 10 November 2011.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 10 November 2011.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000002pPkX2AU'}, 'Id': 'a0POZ000002pPkX2AU', 'Event_Date__c': '2011-11-10', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 10 November 2011.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2011-11.pdf "" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Cost Neutral', 'Summary__c': 'Clarification of May 2011 PTAC minute for ustekinumab (Stelara) for severe chronic plaque psoriasis', 'Formatted_Date__c': 'Nov 2011', 'Status_History__c': 'a132P000000ApwCQAS'}, 'change': None}, {'Summary': {'s': 'Recommended only if cost-neutral to adalimumab.', 'fs': 'Recommended only if cost-neutral to adalimumab.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'Cost Neutral', 'fs': 'Cost Neutral', 'change': None}, 'Links': {'s': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2015-05-updated.pdf"" target=""_blank"">PTAC minutes</a>', 'fs': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2015-05-updated.pdf"" target=""_blank"">PTAC minutes</a>', 'change': None}, 'Formatted_Date': {'s': 'May 2015', 'fs': 'May 2015', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 7 May 2015.', 'fs': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 7 May 2015.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000002pPkb2AE'}, 'Id': 'a0POZ000002pPkb2AE', 'Event_Date__c': '2015-05-07', 'Event_Description__c': 'Clinical advice received from Pharmacology and Therapeutics Advisory Committee (PTAC) at meeting Thursday 7 May 2015.', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<a href=""https://www.pharmac.govt.nz/assets/ptac-minutes-2015-05-updated.pdf"" target=""_blank"">PTAC minutes</a>', 'Outcome__c': 'Cost Neutral', 'Summary__c': 'Recommended only if cost-neutral to adalimumab.', 'Formatted_Date__c': 'May 2015', 'Status_History__c': 'a132P000000AqvNQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2023', 'fs': 'May 2023', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000002pPke2AE'}, 'Id': 'a0POZ000002pPke2AE', 'Event_Date__c': '2023-05-16', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'May 2023', 'Status_History__c': 'a132P000000EDuIQAW'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2023', 'fs': 'May 2023', 'change': None}, 'Event_Description': {'s': 'Assigned to Dermatology Advisory Committee meeting to provide advice on Friday 9 June 2023', 'fs': 'Assigned to Dermatology Advisory Committee meeting to provide advice on Friday 9 June 2023', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000002pPkf2AE'}, 'Id': 'a0POZ000002pPkf2AE', 'Event_Date__c': '2023-05-23', 'Event_Description__c': 'Assigned to Dermatology Advisory Committee meeting to provide advice on Friday 9 June 2023', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'May 2023', 'Status_History__c': 'a132P000000EE02QAG'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee <strong>recommended</strong> that ustekinumab be funded with a <strong>high priority</strong> as a first-line biologic treatment, or <strong>medium priority</strong> as a second-line biologic treatment, for those with severe chronic plaque psoriasis within the context of dermatology treatments, subject to the following Special Authority criteria:</p><p><br></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Initial application – (severe chronic plaque psoriasis) First line biologic </strong><span style=""font-size: 9pt;"">only from a dermatologist. </span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Approvals valid for 4 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">All the following: </span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has &quot;whole body&quot; severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis or </span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis: </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">And</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following: phototherapy, methotrexate, ciclosporin or acitretin</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">And</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">A PASI assessment or Dermatology Life Quality Index (DLQI) assessment has been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course. </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">And</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The most recent PASI or DLQI assessment is no more than 1 month old at the time of application. </span></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">\xa0</strong></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Renewal – (severe chronic plaque psoriasis) </strong><span style=""font-size: 9pt;"">from any relevant prescriber.</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Approvals valid for 6 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Both: </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Either: </span></p><p class=""ql-indent-3""><span style=""font-size: 9pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient’s PASI score has reduced by 75% of more (PASI 75) as compared to baseline PASI prior to commencing ustekinumab; or </span></p><p class=""ql-indent-3""><span style=""font-size: 9pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has a Dermatology Life Quality Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing ustekinumab.\xa0</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">And </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Either: </span></p><p class=""ql-indent-3""><span style=""font-size: 9pt;"">2.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Ustekinumab is to be administered at a maximum dose of 45mg every 12 weeks; or </span></p><p class=""ql-indent-3""><span style=""font-size: 9pt;"">2.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">For patients with body weight greater than 100 kg ustekinumab to be administered at a maximum dose of 90mg every 12 weeks.</span></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee recommended the criteria based on:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The unmet health need of those with severe chronic plaque psoriasis\xa0</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Weight based dosing regimen that may offer health benefits to those with a weight of over 100kg.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The subcutaneous formulation and reduced dosing frequency which reduces infusion time and treatment burden.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The sustainability of the treatment over time.\xa0</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee <strong>recommended</strong> that ustekinumab be funded with a <strong>high priority</strong> as a first-line biologic treatment, or <strong>medium priority</strong> as a second-line biologic treatment, for those with severe chronic plaque psoriasis within the context of dermatology treatments, subject to the following Special Authority criteria:</p><p><br></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Initial application – (severe chronic plaque psoriasis) First line biologic </strong><span style=""font-size: 9pt;"">only from a dermatologist. </span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Approvals valid for 4 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">All the following: </span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has &quot;whole body&quot; severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis or </span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis: </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">And</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following: phototherapy, methotrexate, ciclosporin or acitretin</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">And</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">A PASI assessment or Dermatology Life Quality Index (DLQI) assessment has been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course. </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">And</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The most recent PASI or DLQI assessment is no more than 1 month old at the time of application. </span></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">\xa0</strong></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Renewal – (severe chronic plaque psoriasis) </strong><span style=""font-size: 9pt;"">from any relevant prescriber.</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Approvals valid for 6 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Both: </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Either: </span></p><p class=""ql-indent-3""><span style=""font-size: 9pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient’s PASI score has reduced by 75% of more (PASI 75) as compared to baseline PASI prior to commencing ustekinumab; or </span></p><p class=""ql-indent-3""><span style=""font-size: 9pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has a Dermatology Life Quality Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing ustekinumab.\xa0</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">And </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Either: </span></p><p class=""ql-indent-3""><span style=""font-size: 9pt;"">2.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Ustekinumab is to be administered at a maximum dose of 45mg every 12 weeks; or </span></p><p class=""ql-indent-3""><span style=""font-size: 9pt;"">2.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">For patients with body weight greater than 100 kg ustekinumab to be administered at a maximum dose of 90mg every 12 weeks.</span></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee recommended the criteria based on:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The unmet health need of those with severe chronic plaque psoriasis\xa0</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Weight based dosing regimen that may offer health benefits to those with a weight of over 100kg.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The subcutaneous formulation and reduced dosing frequency which reduces infusion time and treatment burden.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The sustainability of the treatment over time.\xa0</p>', 'change': None}, 'Published_Discussion': {'s': '<h3><em>Māori impact</em></h3><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee discussed the impact of funding ustekinumab for the treatment of chronic plaque psoriasis on Hauora Arotahi - Māori health areas of focus and Māori health outcomes. The Committee noted that a 2014 letter to the New Zealand Medical Journal reported that Māori and Pacific peoples were overrepresented in the numbers that had been treated for psoriasis in the Auckland District Health Board (ADHB) over the\xa05 year period (2009–2014 (<a href=""https://journal.nzma.org.nz/journal-articles/ethnicity-of-psoriasis-patients-an-auckland-perspective"" target=""_blank"">Lee and Lamb, N Z Med J. 2014;127:73-4</a>).</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the subcutaneous formulation, and reduced dosing frequency, would be of benefit.</p><h3><em>Background</em></h3><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that PTAC had reviewed an application for ustekinumab in <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2011-05.pdf"" target=""_blank"">May 2011</a> for the treatment of individuals with severe chronic plaque psoriasis, where it recommended funding of the 45mg dose if cost neutral to other funded biologics, and the 90mg dose if cost neutral to the 45mg dose.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that an application was received in December 2014 requesting ustekinumab be funded for the treatment of plaque psoriasis. PTAC reviewed this application in <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2015-05-updated.pdf"" target=""_blank"">May 2015</a> and recommended ustekinumab be funded only if cost neutral to adalimumab.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted additional evidence and pricing were provided by the supplier in August 2022. Pharmac staff sought advice on the new evidence and the proposed use of ustekinumab as a first- or second-line biologic for the treatment of severe plaque psoriasis.</p><h3><em>Health need</em></h3><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted it had previously reviewed the health need for those with chronic plaque psoriasis in <a href=""https://pharmac.govt.nz/assets/2020-11-25-Dermatology-Subcommittee-Record-Published-26-February-2021.pdf"" target=""_blank"">November 2020</a>.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted PTAC have previously considered that psoriasis is a significant health concern in New Zealand. The PTAC members noted estimates of 76,000 to 114,000 individuals in New Zealand with chronic plaque psoriasis, of whom perhaps 380-570 do not respond adequately to non-biologic systemic treatments (<a href=""https://pharmac.govt.nz/assets/ptac-minutes-2015-05-updated.pdf"" target=""_blank"">May 2015</a>).</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that those with psoriasis are currently treated with phototherapy, acitretin, methotrexate and/or ciclosporin. Under current Special Authority restrictions, those with moderate to severe chronic plaque psoriasis (PASI &gt;10) must have tried, but had an inadequate response to, or experienced intolerable side effects from, at least three of phototherapy, methotrexate, ciclosporin, or acitretin treatment, prior to biologic treatment.</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that many individuals will start on adalimumab as their first biologic, and then switch to either another anti-TNF (such as etanercept) or to secukinumab (an IL-17 inhibitor).</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted a 2014 letter to the New Zealand Medical Journal that reported a review of those treated in the Auckland District Health Board (ADHB) between 2009–2014, that found that of 511 people treated for psoriasis, 26.42% of individuals were of Māori and Pacific ethnicity. As a comparison, the general ADHB population at the time was comprised of 19.1% Māori and Pacific peoples and 52% New Zealand Europeans (<a href=""https://journal.nzma.org.nz/journal-articles/ethnicity-of-psoriasis-patients-an-auckland-perspective"" target=""_blank"">Lee and Lamb, N Z Med J. 2014;127:73-4</a>).</p><h3><em>Health benefit</em></h3><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted ustekinumab is a human IgG1kappa monoclonal antibody directed against interleukins (IL) - 12 and IL-23.</p><p>9.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted the following studies:</p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/34365780/"" target=""_blank"">Ozyurt et al, Turkish journal of medical sciences, 2022, 52:7</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/33289075/"" target=""_blank"">Graier et al, Br J Dermatol, 2021, 184;996-997</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31150706/"" target=""_blank"">Cozzani et al, 2020, J Am Acad Dermatol, 82, 1, 37-43</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31953883/"" target=""_blank"">Shalom et al, JEADV, 2020, 34, 1524-1528</a>:</p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31696543/"" target=""_blank"">Kashimoto et al, J Dermatol. 2020 Jan;47:33-40</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/33816514/"" target=""_blank"">Mourad &amp; Gniadecki, 2021, Front. Med. 7:625755</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/27858976/#:~:text=Results%3A%20For%20the%20398%20patients,0.800%2C%200.755%20and%200.755%20with"" target=""_blank"">Marinas et al, Australas J Dermatol. 2018;59:e11-e14</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/29076754/#:~:text=The%20median%20overall%20drug%20survival,%2C%204%20and%205%2C%20respectively."" target=""_blank"">No et al, J Dermatolog Treat. 2018; 29:460-466</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/27004803/"" target=""_blank"">Vilarrasa et al J Am Acad Dermatol. 2016;74:1066-72</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35656306/"" target=""_blank"">Huang et al, Front Pharmacol. 2022; 13:880985</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/33300595/"" target=""_blank"">Tokuyama et al, Tokai J Exp Clin Med. 2020;45:230-235.</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/30888880/"" target=""_blank"">Puig et al, J Dermatolog Treat. 2020;31:344-351</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/25307931/"" target=""_blank"">Langley et al, Br J Dermatol. 2015;172:1371-8</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/26092291/"" target=""_blank"">Zachariae et al, Eur J Dermatol. 2022;32:530-535</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/32365251/"" target=""_blank"">Bagel et al J Eur Acad Dermatol Venereol. 2021; 35:135-142</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/27663079/"" target=""_blank"">Blauvelt et al, J Am Acad Dermatol. 2017;76:60-69.e9 </a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445726/"" target=""_blank"">Damiani et al, Dermatol Ther. 2019;32:e12793</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/26259989/"" target=""_blank"">Landells et al, J Am Acad Dermatol. 2015;73;594-603</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31583255/"" target=""_blank"">Bai et al, J Immunol Res. 2019;2546161</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/32562551/"" target=""_blank"">Mahil et al Br J Dermatol. 2020;183:638-649</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/29532693/"" target=""_blank"">Bilal et al, J Dermatolog Treat. 2018;29:569-578</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/34888919/"" target=""_blank"">Sun et al, Pediatr Dermatol. 2022;39:42-48</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35603936/"" target=""_blank"">Sbidian et al Cochrane Database Syst Rev. 2022;5:CD011535.</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/28457908/"" target=""_blank"">Jabber-Lopez et al, J Invest Dermatol. 2017;137:1646-1654</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Lee et al, J Dermatol. 2019;46(9):752-758</p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/27515070/"" target=""_blank"">Augustin et al J Eur Acad Dermatol Venereol. 2017;31:294-303</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Beroukhim et al, J Dermatolog Treat. 2016;27:552-555</p><p>9.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered the quality and strength of evidence to be good, including randomised clinical trials, with long term follow up data.</p><p>9.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered the populations and endpoints considered within the pivotal trials to be relevant to New Zealand. The Committee considered that since the initial application for ustekinumab clinical practice and expectations of treatment efficacy had changed and efficacy endpoints of PASI 90 are currently more relevant than PASI 75. The Committee noted there were some differences between publications results, however the Committee considered it was likely that at weeks 44-60, using an endpoint of PASI 90, ustekinumab was broadly comparable to adalimumab. The Committee considered that long-term durability was likely to be slightly better with ustekinumab compared to funded agents such as adalimumab and secukinumab.</p><p>9.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted in first line biologic treatment ustekinumab had the longest drug survival rate compared to adalimumab, etanercept, ixekizumab, and secukinumab. (<a href=""https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.19701"" target=""_blank"">Graier et al. Br J Dermatol 2021.184, pp1094–1105</a>). The Committee noted the <a href=""https://pubmed.ncbi.nlm.nih.gov/30375427/"" target=""_blank"">Lin et al, Sci Rep. 2018;8:16068</a> meta-analysis that also reported ustekinumab was associated with the highest drug survival in those who had and had not received previous biologic treatments.\xa0</p><p>9.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted a publication reporting there was no difference in drug survival in second line treatment between ustekinumab and secukinumab, infliximab, adalimumab and etanercept (<a href=""https://www.jaad.org/article/S0190-9622(19)30868-0/pdf"" target=""_blank"">Cozzani et al. J Am Acad Dermatol. 2020;82:37-44</a>).</p><p>9.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted a meta-analysis comparing health benefit of biologics in first line treatment, this reported risankizumab and guselkumab offered greater efficacy at weeks 44-60 in improvement of PASI 90 score compared to ustekinumab, at 79.4, 76.5 and 52.4% respectively (<a href=""https://pubmed.ncbi.nlm.nih.gov/32022825/"" target=""_blank"">Armstrong et al. JAMA Dermatol. 2020;156:258-69</a>).</p><p>9.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that ustekinumab has a weight-based dosing, with 45mg recommended for those under 100kg, and 90mg for those with a weight greater than 100kg. The Committee considered a significant number of people with psoriasis in New Zealand have a weight greater than 100 kg and would benefit from weight-based dosing including\xa0Māori and Pacific peoples with psoriasis,</p><h3><em>Suitability</em></h3><p>9.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered that the subcutaneous formulation offers an advantage over infliximab, which is administered by infusion, by reducing the time needed for administration and travel for those undergoing treatment. The Committee noted the subcutaneous formulation would result in a reduction in the demand for infusion services for individuals who would otherwise have received infliximab intravenous infusions.</p><p>9.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted ustekinumab offered a reduced dosing frequency, with maintenance dosing every 12 weeks, in comparison to etanercept, adalimumab and secukinumab which are administered once weekly, fortnightly, and monthly respectively.</p><h3><em>Summary for assessment</em></h3><p>9.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The <span style=""color: black;"">Advisory Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for ustekinumab if it were to be funded in New Zealand for first- or second-line treatment of chronic severe plaque psoriasis. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Advisory Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</span></p><p><img src=""/apptracker/servlet/rtaImage?eid=a0POZ000002pPkg&amp;feoid=00N2P000000YsIc&amp;refid=0EMOZ000000is7z"" alt=""image.png""></img></p>', 'fs': '<h3><em>Māori impact</em></h3><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee discussed the impact of funding ustekinumab for the treatment of chronic plaque psoriasis on Hauora Arotahi - Māori health areas of focus and Māori health outcomes. The Committee noted that a 2014 letter to the New Zealand Medical Journal reported that Māori and Pacific peoples were overrepresented in the numbers that had been treated for psoriasis in the Auckland District Health Board (ADHB) over the\xa05 year period (2009–2014 (<a href=""https://journal.nzma.org.nz/journal-articles/ethnicity-of-psoriasis-patients-an-auckland-perspective"" target=""_blank"">Lee and Lamb, N Z Med J. 2014;127:73-4</a>).</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the subcutaneous formulation, and reduced dosing frequency, would be of benefit.</p><h3><em>Background</em></h3><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that PTAC had reviewed an application for ustekinumab in <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2011-05.pdf"" target=""_blank"">May 2011</a> for the treatment of individuals with severe chronic plaque psoriasis, where it recommended funding of the 45mg dose if cost neutral to other funded biologics, and the 90mg dose if cost neutral to the 45mg dose.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that an application was received in December 2014 requesting ustekinumab be funded for the treatment of plaque psoriasis. PTAC reviewed this application in <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2015-05-updated.pdf"" target=""_blank"">May 2015</a> and recommended ustekinumab be funded only if cost neutral to adalimumab.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted additional evidence and pricing were provided by the supplier in August 2022. Pharmac staff sought advice on the new evidence and the proposed use of ustekinumab as a first- or second-line biologic for the treatment of severe plaque psoriasis.</p><h3><em>Health need</em></h3><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted it had previously reviewed the health need for those with chronic plaque psoriasis in <a href=""https://pharmac.govt.nz/assets/2020-11-25-Dermatology-Subcommittee-Record-Published-26-February-2021.pdf"" target=""_blank"">November 2020</a>.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted PTAC have previously considered that psoriasis is a significant health concern in New Zealand. The PTAC members noted estimates of 76,000 to 114,000 individuals in New Zealand with chronic plaque psoriasis, of whom perhaps 380-570 do not respond adequately to non-biologic systemic treatments (<a href=""https://pharmac.govt.nz/assets/ptac-minutes-2015-05-updated.pdf"" target=""_blank"">May 2015</a>).</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that those with psoriasis are currently treated with phototherapy, acitretin, methotrexate and/or ciclosporin. Under current Special Authority restrictions, those with moderate to severe chronic plaque psoriasis (PASI &gt;10) must have tried, but had an inadequate response to, or experienced intolerable side effects from, at least three of phototherapy, methotrexate, ciclosporin, or acitretin treatment, prior to biologic treatment.</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that many individuals will start on adalimumab as their first biologic, and then switch to either another anti-TNF (such as etanercept) or to secukinumab (an IL-17 inhibitor).</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted a 2014 letter to the New Zealand Medical Journal that reported a review of those treated in the Auckland District Health Board (ADHB) between 2009–2014, that found that of 511 people treated for psoriasis, 26.42% of individuals were of Māori and Pacific ethnicity. As a comparison, the general ADHB population at the time was comprised of 19.1% Māori and Pacific peoples and 52% New Zealand Europeans (<a href=""https://journal.nzma.org.nz/journal-articles/ethnicity-of-psoriasis-patients-an-auckland-perspective"" target=""_blank"">Lee and Lamb, N Z Med J. 2014;127:73-4</a>).</p><h3><em>Health benefit</em></h3><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted ustekinumab is a human IgG1kappa monoclonal antibody directed against interleukins (IL) - 12 and IL-23.</p><p>9.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted the following studies:</p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/34365780/"" target=""_blank"">Ozyurt et al, Turkish journal of medical sciences, 2022, 52:7</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/33289075/"" target=""_blank"">Graier et al, Br J Dermatol, 2021, 184;996-997</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31150706/"" target=""_blank"">Cozzani et al, 2020, J Am Acad Dermatol, 82, 1, 37-43</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31953883/"" target=""_blank"">Shalom et al, JEADV, 2020, 34, 1524-1528</a>:</p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31696543/"" target=""_blank"">Kashimoto et al, J Dermatol. 2020 Jan;47:33-40</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/33816514/"" target=""_blank"">Mourad &amp; Gniadecki, 2021, Front. Med. 7:625755</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/27858976/#:~:text=Results%3A%20For%20the%20398%20patients,0.800%2C%200.755%20and%200.755%20with"" target=""_blank"">Marinas et al, Australas J Dermatol. 2018;59:e11-e14</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/29076754/#:~:text=The%20median%20overall%20drug%20survival,%2C%204%20and%205%2C%20respectively."" target=""_blank"">No et al, J Dermatolog Treat. 2018; 29:460-466</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/27004803/"" target=""_blank"">Vilarrasa et al J Am Acad Dermatol. 2016;74:1066-72</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35656306/"" target=""_blank"">Huang et al, Front Pharmacol. 2022; 13:880985</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/33300595/"" target=""_blank"">Tokuyama et al, Tokai J Exp Clin Med. 2020;45:230-235.</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/30888880/"" target=""_blank"">Puig et al, J Dermatolog Treat. 2020;31:344-351</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/25307931/"" target=""_blank"">Langley et al, Br J Dermatol. 2015;172:1371-8</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/26092291/"" target=""_blank"">Zachariae et al, Eur J Dermatol. 2022;32:530-535</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/32365251/"" target=""_blank"">Bagel et al J Eur Acad Dermatol Venereol. 2021; 35:135-142</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/27663079/"" target=""_blank"">Blauvelt et al, J Am Acad Dermatol. 2017;76:60-69.e9 </a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445726/"" target=""_blank"">Damiani et al, Dermatol Ther. 2019;32:e12793</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/26259989/"" target=""_blank"">Landells et al, J Am Acad Dermatol. 2015;73;594-603</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31583255/"" target=""_blank"">Bai et al, J Immunol Res. 2019;2546161</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/32562551/"" target=""_blank"">Mahil et al Br J Dermatol. 2020;183:638-649</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/29532693/"" target=""_blank"">Bilal et al, J Dermatolog Treat. 2018;29:569-578</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/34888919/"" target=""_blank"">Sun et al, Pediatr Dermatol. 2022;39:42-48</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35603936/"" target=""_blank"">Sbidian et al Cochrane Database Syst Rev. 2022;5:CD011535.</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/28457908/"" target=""_blank"">Jabber-Lopez et al, J Invest Dermatol. 2017;137:1646-1654</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Lee et al, J Dermatol. 2019;46(9):752-758</p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/27515070/"" target=""_blank"">Augustin et al J Eur Acad Dermatol Venereol. 2017;31:294-303</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Beroukhim et al, J Dermatolog Treat. 2016;27:552-555</p><p>9.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered the quality and strength of evidence to be good, including randomised clinical trials, with long term follow up data.</p><p>9.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered the populations and endpoints considered within the pivotal trials to be relevant to New Zealand. The Committee considered that since the initial application for ustekinumab clinical practice and expectations of treatment efficacy had changed and efficacy endpoints of PASI 90 are currently more relevant than PASI 75. The Committee noted there were some differences between publications results, however the Committee considered it was likely that at weeks 44-60, using an endpoint of PASI 90, ustekinumab was broadly comparable to adalimumab. The Committee considered that long-term durability was likely to be slightly better with ustekinumab compared to funded agents such as adalimumab and secukinumab.</p><p>9.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted in first line biologic treatment ustekinumab had the longest drug survival rate compared to adalimumab, etanercept, ixekizumab, and secukinumab. (<a href=""https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.19701"" target=""_blank"">Graier et al. Br J Dermatol 2021.184, pp1094–1105</a>). The Committee noted the <a href=""https://pubmed.ncbi.nlm.nih.gov/30375427/"" target=""_blank"">Lin et al, Sci Rep. 2018;8:16068</a> meta-analysis that also reported ustekinumab was associated with the highest drug survival in those who had and had not received previous biologic treatments.\xa0</p><p>9.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted a publication reporting there was no difference in drug survival in second line treatment between ustekinumab and secukinumab, infliximab, adalimumab and etanercept (<a href=""https://www.jaad.org/article/S0190-9622(19)30868-0/pdf"" target=""_blank"">Cozzani et al. J Am Acad Dermatol. 2020;82:37-44</a>).</p><p>9.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted a meta-analysis comparing health benefit of biologics in first line treatment, this reported risankizumab and guselkumab offered greater efficacy at weeks 44-60 in improvement of PASI 90 score compared to ustekinumab, at 79.4, 76.5 and 52.4% respectively (<a href=""https://pubmed.ncbi.nlm.nih.gov/32022825/"" target=""_blank"">Armstrong et al. JAMA Dermatol. 2020;156:258-69</a>).</p><p>9.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that ustekinumab has a weight-based dosing, with 45mg recommended for those under 100kg, and 90mg for those with a weight greater than 100kg. The Committee considered a significant number of people with psoriasis in New Zealand have a weight greater than 100 kg and would benefit from weight-based dosing including\xa0Māori and Pacific peoples with psoriasis,</p><h3><em>Suitability</em></h3><p>9.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered that the subcutaneous formulation offers an advantage over infliximab, which is administered by infusion, by reducing the time needed for administration and travel for those undergoing treatment. The Committee noted the subcutaneous formulation would result in a reduction in the demand for infusion services for individuals who would otherwise have received infliximab intravenous infusions.</p><p>9.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted ustekinumab offered a reduced dosing frequency, with maintenance dosing every 12 weeks, in comparison to etanercept, adalimumab and secukinumab which are administered once weekly, fortnightly, and monthly respectively.</p><h3><em>Summary for assessment</em></h3><p>9.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The <span style=""color: black;"">Advisory Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for ustekinumab if it were to be funded in New Zealand for first- or second-line treatment of chronic severe plaque psoriasis. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Advisory Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</span></p><p><img src=""/apptracker/servlet/rtaImage?eid=a0POZ000002pPkg&amp;feoid=00N2P000000YsIc&amp;refid=0EMOZ000000is7z"" alt=""image.png""></img></p>', 'change': None}, 'Published_Application': {'s': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee reviewed the application for ustekinumab for the treatment of chronic severe plaque psoriasis.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'fs': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee reviewed the application for ustekinumab for the treatment of chronic severe plaque psoriasis.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': 'High', 'fs': 'High', 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2023', 'fs': 'Nov 2023', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from Dermatology Advisory Committee at meeting Friday 9 June 2023.', 'fs': 'Clinical advice received from Dermatology Advisory Committee at meeting Friday 9 June 2023.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000002pPkg2AE'}, 'Id': 'a0POZ000002pPkg2AE', 'Event_Date__c': '2023-11-29', 'Event_Description__c': 'Clinical advice received from Dermatology Advisory Committee at meeting Friday 9 June 2023.', 'Stage__c': 'Seeking Clinical Advice', 'Outcome__c': 'High', 'Formatted_Date__c': 'Nov 2023', 'Published_Recommendation__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee <strong>recommended</strong> that ustekinumab be funded with a <strong>high priority</strong> as a first-line biologic treatment, or <strong>medium priority</strong> as a second-line biologic treatment, for those with severe chronic plaque psoriasis within the context of dermatology treatments, subject to the following Special Authority criteria:</p><p><br></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Initial application – (severe chronic plaque psoriasis) First line biologic </strong><span style=""font-size: 9pt;"">only from a dermatologist. </span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Approvals valid for 4 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">All the following: </span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has &quot;whole body&quot; severe chronic plaque psoriasis with a Psoriasis Area and Severity Index (PASI) score of greater than 10, where lesions have been present for at least 6 months from the time of initial diagnosis or </span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has severe chronic plaque psoriasis of the face, or palm of a hand or sole of a foot, where the plaque or plaques have been present for at least 6 months from the time of initial diagnosis: </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">And</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">3.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has tried, but had an inadequate response (see Note) to, or has experienced intolerable side effects from, at least three of the following: phototherapy, methotrexate, ciclosporin or acitretin</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">And</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">4.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">A PASI assessment or Dermatology Life Quality Index (DLQI) assessment has been completed for at least the most recent prior treatment course, preferably while still on treatment but no longer than 1 month following cessation of each prior treatment course. </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">And</span></p><p class=""ql-indent-2"" style=""text-align: justify;""><span style=""font-size: 9pt;"">5.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">The most recent PASI or DLQI assessment is no more than 1 month old at the time of application. </span></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">\xa0</strong></p><p class=""ql-indent-1""><strong style=""font-size: 9pt;"">Renewal – (severe chronic plaque psoriasis) </strong><span style=""font-size: 9pt;"">from any relevant prescriber.</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Approvals valid for 6 months for applications meeting the following criteria:</span></p><p class=""ql-indent-1""><span style=""font-size: 9pt;"">Both: </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Either: </span></p><p class=""ql-indent-3""><span style=""font-size: 9pt;"">1.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient’s PASI score has reduced by 75% of more (PASI 75) as compared to baseline PASI prior to commencing ustekinumab; or </span></p><p class=""ql-indent-3""><span style=""font-size: 9pt;"">1.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Patient has a Dermatology Life Quality Index (DLQI) improvement of 5 or more, as compared to baseline DLQI prior to commencing ustekinumab.\xa0</span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">And </span></p><p class=""ql-indent-2""><span style=""font-size: 9pt;"">2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Either: </span></p><p class=""ql-indent-3""><span style=""font-size: 9pt;"">2.1.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">Ustekinumab is to be administered at a maximum dose of 45mg every 12 weeks; or </span></p><p class=""ql-indent-3""><span style=""font-size: 9pt;"">2.2.</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><span style=""font-size: 9pt;"">For patients with body weight greater than 100 kg ustekinumab to be administered at a maximum dose of 90mg every 12 weeks.</span></p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee recommended the criteria based on:</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The unmet health need of those with severe chronic plaque psoriasis\xa0</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Weight based dosing regimen that may offer health benefits to those with a weight of over 100kg.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The subcutaneous formulation and reduced dosing frequency which reduces infusion time and treatment burden.</p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>The sustainability of the treatment over time.\xa0</p>', 'Published_Application__c': '<p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee reviewed the application for ustekinumab for the treatment of chronic severe plaque psoriasis.</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Advisory Committee took into account, where applicable, Pharmac’s relevant decision-making framework when considering this agenda item.\xa0</p>', 'Published_Discussion__c': '<h3><em>Māori impact</em></h3><p>1.1.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee discussed the impact of funding ustekinumab for the treatment of chronic plaque psoriasis on Hauora Arotahi - Māori health areas of focus and Māori health outcomes. The Committee noted that a 2014 letter to the New Zealand Medical Journal reported that Māori and Pacific peoples were overrepresented in the numbers that had been treated for psoriasis in the Auckland District Health Board (ADHB) over the\xa05 year period (2009–2014 (<a href=""https://journal.nzma.org.nz/journal-articles/ethnicity-of-psoriasis-patients-an-auckland-perspective"" target=""_blank"">Lee and Lamb, N Z Med J. 2014;127:73-4</a>).</p><p>1.2.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted the subcutaneous formulation, and reduced dosing frequency, would be of benefit.</p><h3><em>Background</em></h3><p>1.3.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that PTAC had reviewed an application for ustekinumab in <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2011-05.pdf"" target=""_blank"">May 2011</a> for the treatment of individuals with severe chronic plaque psoriasis, where it recommended funding of the 45mg dose if cost neutral to other funded biologics, and the 90mg dose if cost neutral to the 45mg dose.</p><p>1.4.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that an application was received in December 2014 requesting ustekinumab be funded for the treatment of plaque psoriasis. PTAC reviewed this application in <a href=""https://pharmac.govt.nz/assets/ptac-minutes-2015-05-updated.pdf"" target=""_blank"">May 2015</a> and recommended ustekinumab be funded only if cost neutral to adalimumab.</p><p>1.5.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted additional evidence and pricing were provided by the supplier in August 2022. Pharmac staff sought advice on the new evidence and the proposed use of ustekinumab as a first- or second-line biologic for the treatment of severe plaque psoriasis.</p><h3><em>Health need</em></h3><p>1.6.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted it had previously reviewed the health need for those with chronic plaque psoriasis in <a href=""https://pharmac.govt.nz/assets/2020-11-25-Dermatology-Subcommittee-Record-Published-26-February-2021.pdf"" target=""_blank"">November 2020</a>.</p><p>1.7.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted PTAC have previously considered that psoriasis is a significant health concern in New Zealand. The PTAC members noted estimates of 76,000 to 114,000 individuals in New Zealand with chronic plaque psoriasis, of whom perhaps 380-570 do not respond adequately to non-biologic systemic treatments (<a href=""https://pharmac.govt.nz/assets/ptac-minutes-2015-05-updated.pdf"" target=""_blank"">May 2015</a>).</p><p>1.8.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that those with psoriasis are currently treated with phototherapy, acitretin, methotrexate and/or ciclosporin. Under current Special Authority restrictions, those with moderate to severe chronic plaque psoriasis (PASI &gt;10) must have tried, but had an inadequate response to, or experienced intolerable side effects from, at least three of phototherapy, methotrexate, ciclosporin, or acitretin treatment, prior to biologic treatment.</p><p>1.9.<span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0</span>The Committee noted that many individuals will start on adalimumab as their first biologic, and then switch to either another anti-TNF (such as etanercept) or to secukinumab (an IL-17 inhibitor).</p><p>1.10.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted a 2014 letter to the New Zealand Medical Journal that reported a review of those treated in the Auckland District Health Board (ADHB) between 2009–2014, that found that of 511 people treated for psoriasis, 26.42% of individuals were of Māori and Pacific ethnicity. As a comparison, the general ADHB population at the time was comprised of 19.1% Māori and Pacific peoples and 52% New Zealand Europeans (<a href=""https://journal.nzma.org.nz/journal-articles/ethnicity-of-psoriasis-patients-an-auckland-perspective"" target=""_blank"">Lee and Lamb, N Z Med J. 2014;127:73-4</a>).</p><h3><em>Health benefit</em></h3><p>1.11.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted ustekinumab is a human IgG1kappa monoclonal antibody directed against interleukins (IL) - 12 and IL-23.</p><p>9.12.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted the following studies:</p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/34365780/"" target=""_blank"">Ozyurt et al, Turkish journal of medical sciences, 2022, 52:7</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/33289075/"" target=""_blank"">Graier et al, Br J Dermatol, 2021, 184;996-997</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31150706/"" target=""_blank"">Cozzani et al, 2020, J Am Acad Dermatol, 82, 1, 37-43</a></p><p class=""ql-indent-1""><span style=""font-family: Symbol;"">·</span><span style=""font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31953883/"" target=""_blank"">Shalom et al, JEADV, 2020, 34, 1524-1528</a>:</p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31696543/"" target=""_blank"">Kashimoto et al, J Dermatol. 2020 Jan;47:33-40</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/33816514/"" target=""_blank"">Mourad &amp; Gniadecki, 2021, Front. Med. 7:625755</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/27858976/#:~:text=Results%3A%20For%20the%20398%20patients,0.800%2C%200.755%20and%200.755%20with"" target=""_blank"">Marinas et al, Australas J Dermatol. 2018;59:e11-e14</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/29076754/#:~:text=The%20median%20overall%20drug%20survival,%2C%204%20and%205%2C%20respectively."" target=""_blank"">No et al, J Dermatolog Treat. 2018; 29:460-466</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/27004803/"" target=""_blank"">Vilarrasa et al J Am Acad Dermatol. 2016;74:1066-72</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35656306/"" target=""_blank"">Huang et al, Front Pharmacol. 2022; 13:880985</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/33300595/"" target=""_blank"">Tokuyama et al, Tokai J Exp Clin Med. 2020;45:230-235.</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/30888880/"" target=""_blank"">Puig et al, J Dermatolog Treat. 2020;31:344-351</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/25307931/"" target=""_blank"">Langley et al, Br J Dermatol. 2015;172:1371-8</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/26092291/"" target=""_blank"">Zachariae et al, Eur J Dermatol. 2022;32:530-535</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/32365251/"" target=""_blank"">Bagel et al J Eur Acad Dermatol Venereol. 2021; 35:135-142</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/27663079/"" target=""_blank"">Blauvelt et al, J Am Acad Dermatol. 2017;76:60-69.e9 </a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6445726/"" target=""_blank"">Damiani et al, Dermatol Ther. 2019;32:e12793</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/26259989/"" target=""_blank"">Landells et al, J Am Acad Dermatol. 2015;73;594-603</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/31583255/"" target=""_blank"">Bai et al, J Immunol Res. 2019;2546161</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/32562551/"" target=""_blank"">Mahil et al Br J Dermatol. 2020;183:638-649</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/29532693/"" target=""_blank"">Bilal et al, J Dermatolog Treat. 2018;29:569-578</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/34888919/"" target=""_blank"">Sun et al, Pediatr Dermatol. 2022;39:42-48</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/35603936/"" target=""_blank"">Sbidian et al Cochrane Database Syst Rev. 2022;5:CD011535.</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/28457908/"" target=""_blank"">Jabber-Lopez et al, J Invest Dermatol. 2017;137:1646-1654</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Lee et al, J Dermatol. 2019;46(9):752-758</p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span><a href=""https://pubmed.ncbi.nlm.nih.gov/27515070/"" target=""_blank"">Augustin et al J Eur Acad Dermatol Venereol. 2017;31:294-303</a></p><p class=""ql-indent-1""><span style=""color: windowtext; font-family: Symbol;"">·</span><span style=""color: windowtext; font-size: 7pt;"">\xa0\xa0\xa0\xa0\xa0\xa0\xa0\xa0</span>Beroukhim et al, J Dermatolog Treat. 2016;27:552-555</p><p>9.13.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered the quality and strength of evidence to be good, including randomised clinical trials, with long term follow up data.</p><p>9.14.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered the populations and endpoints considered within the pivotal trials to be relevant to New Zealand. The Committee considered that since the initial application for ustekinumab clinical practice and expectations of treatment efficacy had changed and efficacy endpoints of PASI 90 are currently more relevant than PASI 75. The Committee noted there were some differences between publications results, however the Committee considered it was likely that at weeks 44-60, using an endpoint of PASI 90, ustekinumab was broadly comparable to adalimumab. The Committee considered that long-term durability was likely to be slightly better with ustekinumab compared to funded agents such as adalimumab and secukinumab.</p><p>9.15.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted in first line biologic treatment ustekinumab had the longest drug survival rate compared to adalimumab, etanercept, ixekizumab, and secukinumab. (<a href=""https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjd.19701"" target=""_blank"">Graier et al. Br J Dermatol 2021.184, pp1094–1105</a>). The Committee noted the <a href=""https://pubmed.ncbi.nlm.nih.gov/30375427/"" target=""_blank"">Lin et al, Sci Rep. 2018;8:16068</a> meta-analysis that also reported ustekinumab was associated with the highest drug survival in those who had and had not received previous biologic treatments.\xa0</p><p>9.16.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted a publication reporting there was no difference in drug survival in second line treatment between ustekinumab and secukinumab, infliximab, adalimumab and etanercept (<a href=""https://www.jaad.org/article/S0190-9622(19)30868-0/pdf"" target=""_blank"">Cozzani et al. J Am Acad Dermatol. 2020;82:37-44</a>).</p><p>9.17.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted a meta-analysis comparing health benefit of biologics in first line treatment, this reported risankizumab and guselkumab offered greater efficacy at weeks 44-60 in improvement of PASI 90 score compared to ustekinumab, at 79.4, 76.5 and 52.4% respectively (<a href=""https://pubmed.ncbi.nlm.nih.gov/32022825/"" target=""_blank"">Armstrong et al. JAMA Dermatol. 2020;156:258-69</a>).</p><p>9.18.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted that ustekinumab has a weight-based dosing, with 45mg recommended for those under 100kg, and 90mg for those with a weight greater than 100kg. The Committee considered a significant number of people with psoriasis in New Zealand have a weight greater than 100 kg and would benefit from weight-based dosing including\xa0Māori and Pacific peoples with psoriasis,</p><h3><em>Suitability</em></h3><p>9.19.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee considered that the subcutaneous formulation offers an advantage over infliximab, which is administered by infusion, by reducing the time needed for administration and travel for those undergoing treatment. The Committee noted the subcutaneous formulation would result in a reduction in the demand for infusion services for individuals who would otherwise have received infliximab intravenous infusions.</p><p>9.20.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The Committee noted ustekinumab offered a reduced dosing frequency, with maintenance dosing every 12 weeks, in comparison to etanercept, adalimumab and secukinumab which are administered once weekly, fortnightly, and monthly respectively.</p><h3><em>Summary for assessment</em></h3><p>9.21.<span style=""font-size: 7pt;"">\xa0\xa0\xa0</span>The <span style=""color: black;"">Advisory Committee considered that the table below summarises its interpretation of the most appropriate PICO (population, intervention, comparator, outcomes) information for ustekinumab if it were to be funded in New Zealand for first- or second-line treatment of chronic severe plaque psoriasis. This PICO captures key clinical aspects of the proposal and may be used to frame any future economic assessment by Pharmac staff. This PICO is based on the Advisory Committee’s assessment at this time and may differ from that requested by the applicant. The PICO may change based on new information, additional clinical advice, or further analysis by Pharmac staff.</span></p><p><img src=""/apptracker/servlet/rtaImage?eid=a0POZ000002pPkg&amp;feoid=00N2P000000YsIc&amp;refid=0EMOZ000000is7z"" alt=""image.png""></img></p>', 'Status_History__c': 'a13OZ000004Hb0yYAC'}, 'change': None}]",Mar 2011,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2015', 'fs': 'May 2015', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000002pPkc2AE'}, 'Id': 'a0POZ000002pPkc2AE', 'Event_Date__c': '2015-05-11', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'May 2015', 'Status_History__c': 'a132P000000D0iZQAS'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2023', 'fs': 'Dec 2023', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000002pPkh2AE'}, 'Id': 'a0POZ000002pPkh2AE', 'Event_Date__c': '2023-12-04', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Dec 2023', 'Status_History__c': 'a13OZ000004BEBpYAO'}, 'change': None}]",May 2015,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'May 2011', 'fs': 'May 2011', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000002pPkU2AU'}, 'Id': 'a0POZ000002pPkU2AU', 'Event_Date__c': '2011-05-01', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'May 2011', 'Status_History__c': 'a132P000000ApofQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Nov 2013', 'fs': 'Nov 2013', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000002pPkY2AU'}, 'Id': 'a0POZ000002pPkY2AU', 'Event_Date__c': '2013-11-05', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Nov 2013', 'Status_History__c': 'a132P000000AqWRQA0'}, 'change': None}, {'Summary': {'s': 'Letter from the New Zealand Dermatological Society regarding funding for ustekinumab.', 'fs': 'Letter from the New Zealand Dermatological Society regarding funding for ustekinumab.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2014', 'fs': 'Mar 2014', 'change': None}, 'Event_Description': {'s': 'Received Additional Information', 'fs': 'Received Additional Information', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000002pPkZ2AU'}, 'Id': 'a0POZ000002pPkZ2AU', 'Event_Date__c': '2014-03-27', 'Event_Description__c': 'Received Additional Information', 'Stage__c': 'Options Compared', 'Summary__c': 'Letter from the New Zealand Dermatological Society regarding funding for ustekinumab.', 'Formatted_Date__c': 'Mar 2014', 'Status_History__c': 'a132P000000AqdWQAS'}, 'change': None}, {'Summary': {'s': 'Application from a clinician, on behalf of the New Zealand Dermatological Society.', 'fs': 'Application from a clinician, on behalf of the New Zealand Dermatological Society.', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2014', 'fs': 'Dec 2014', 'change': None}, 'Event_Description': {'s': 'Received Additional Information', 'fs': 'Received Additional Information', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000002pPka2AE'}, 'Id': 'a0POZ000002pPka2AE', 'Event_Date__c': '2014-12-24', 'Event_Description__c': 'Received Additional Information', 'Stage__c': 'Options Compared', 'Summary__c': 'Application from a clinician, on behalf of the New Zealand Dermatological Society.', 'Formatted_Date__c': 'Dec 2014', 'Status_History__c': 'a132P000000Aqr5QAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2015', 'fs': 'Jun 2015', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000002pPkd2AE'}, 'Id': 'a0POZ000002pPkd2AE', 'Event_Date__c': '2015-06-11', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jun 2015', 'Status_History__c': 'a132P000000D0ieQAC'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Dec 2023', 'fs': 'Dec 2023', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v62.0/sobjects/Application_Event__c/a0POZ000002pPki2AE'}, 'Id': 'a0POZ000002pPki2AE', 'Event_Date__c': '2023-12-07', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Dec 2023', 'Status_History__c': 'a13OZ000004JtLJYA0'}, 'change': None}]",May 2011,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,,,False,False
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,,,False,False
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,,,False,False
